NCCN treatment guidelines for advanced gastric cancer

Share This Post

The 2016 NCCN Clinical Guidelines for Gastric Cancer updated the systemic treatment plan for metastatic or locally advanced gastric cancer in the first edition (NCCN.2016.V1).

Among them, the DCF in the original first-line preferred plan was cancelled, the DCF improvement, ECF and ECF improvement were moved to other first-line programs, and docetaxel irinotecan in the other first-line programs was canceled.

The updated first-line preferred plan is 6 types in category 2 and 18 types in other types; the second-line preferred plan is 9 types in category 4 and 4 types in other types 3. It is hereby sorted as follows:


D-Docetaxel, docetaxel;

E-Epirubicin, epirubicin;

F-Fluorouracil (5-FU), fluorouracil;

FOL-Folinic acid (leucovorin), calcium leucovorin;

I- Irinotecan, irinotecan;

O / OX-Oxaliplatin, Oxaliplatin;

P-Cisplatin, cisplatin (PDD);

R-Ramucirumab, Ramucirumab

T-Paclitaxel, paclitaxel;

X / XEL-Capecitabine, capecitabine;

FOLFOX-A series of chemotherapy regimens for the treatment of gastric or colorectal cancer composed of a combination of calcium folinate and fluorouracil combined with different doses of oxaliplatin is often called FOLFOX regimen

The chemotherapy regimen of XELOX-capecitabine combined with oxaliplatin is often referred to as the XELOX regimen

First-line preferred solution

HER2-neu overexpression of metastatic adenocarcinoma should be combined with trastuzumab for first-line non-anthracycline chemotherapy.

Specific plan: Trastuzumab intravenous injection for the first time at 8 mg / kg, day 1, followed by 6 mg / kg intravenous injection, 21 days / cycle; or for the first intravenous injection at 6 mg / kg, day 1, then 4 mg / kg intravenous injection, 14 days / cycle.

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

Claudin18.2-targeted CAR-T cell therapy brings complete remission in advanced pancreatic cancer patient A case report
CAR T-Cell therapy

Claudin18.2-targeted CAR-T cell therapy brings complete remission in advanced pancreatic cancer patient : A case report

Claudin18.2-targeted CAR-T cell therapy has shown remarkable potential in treating advanced pancreatic cancer, as highlighted in a recent case report. This innovative approach led to complete remission in a patient with advanced disease, underscoring the promise of targeted immunotherapy. By leveraging the specific expression of Claudin18.2 on cancer cells, this therapy offers a precision-based treatment, heralding a new era in pancreatic cancer management with significant clinical implications.

What is the treatment after BCMA CAR T failed in RR multiple myeloma cases
CAR T-Cell therapy

What is the treatment after BCMA CAR T failed in R/R multiple myeloma cases?

For people with relapsed or refractory multiple myeloma, BCMA CAR T-cell therapy might not work. Other treatments, such as bispecific antibodies, other CAR T-cell therapies that target different antigens, and combination regimens with immunomodulatory drugs, proteasome inhibitors, and monoclonal antibodies, can still be used. OriCAR-017 is another immunotherapy that is under trial and is expected to be launched soon. Clinical trials offer experimental treatments, providing access to novel therapies. Tailored approaches based on patient-specific factors and emerging research are crucial for improving outcomes in this challenging scenario.

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

Start chat
We Are Online! Chat With Us!
Scan the code

Welcome to CancerFax !

CancerFax is a pioneering platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies like CAR T-Cell therapy, TIL therapy, and clinical trials worldwide.

Let us know what we can do for you.

1) Cancer treatment abroad?
2) CAR T-Cell therapy
3) Cancer vaccine
4) Online video consultation
5) Proton therapy